Navigate Through Our Insights

Client Alert March 24, 2025

Even Marketing Materials Can Subject Issuers to Securities Fraud Claim

Our lawyers discuss a recent case which highlighted that marketing materials may form the basis of a warning letter or a securities fraud claim.

Webcasts March 19, 2025

Webcast: Life Sciences 2025 Outlook Webcast Series: Capital Markets

Join our team of seasoned attorneys and industry leaders for part two of this webcast series, where we provide an integrated outlook on capital markets in the life sciences, identifying trends and uncertainties that will shape the year ahead.

Webcasts March 12, 2025

Webcast: Life Sciences 2025 Outlook Webcast Series: Royalty Finance

Join our team of seasoned attorneys and industry leaders where we provide an integrated outlook on the industry’s key areas, including mergers and acquisitions (M&A), capital markets, royalty finance, collaborations and licensing, regulatory policies, and AI, identifying trends and uncertainties that will shape the year ahead.

Publications March 3, 2025

Royalty Finance Tracker

The Gibson Dunn team has represented clients in royalty finance transactions with a total aggregate value of approximately $8 Billion.

Client Alert January 22, 2025

Life Sciences 2025 Outlook

The life sciences industry is entering 2025 with a largely favorable set of catalysts for the coming year, but also …

Client Alert December 20, 2024

Executive Email Can Expose Public Companies to Securities Fraud Claim

Our lawyers provide analysis of Pizzuto v. Homology Meds., Inc.

Firm News October 31, 2024

Gibson Dunn Advises Jade Biosciences on Merger with Aerovate Therapeutics, Inc. and Concurrent Private Placement

Gibson Dunn is advising Jade Biosciences on its merger with Aerovate Therapeutics, Inc. and the concurrent $300 million private placement of shares of its common stock and pre-funded warrants to a syndicate of healthcare investors. 

Accolades October 18, 2024

Lawdragon Names 45 Partners Among its 500 Leading Dealmakers in America 2025

Lawdragon named 45 partners to its 500 Leading Dealmakers in America 2025, which honors “the eminents of M&A, the power players of private equity, the consiglieres of capital markets.”